22:41 , Jun 20, 2019 |  BC Innovations  |  Targets & Mechanisms

Moving beyond the active site: why allostery is newly in fashion

A new crop of companies is creating tools to systematize development of allosteric protein inhibitors, finally moving industry beyond the one-off compounds that have been found by accident. Allosteric pockets on proteins have long been...
21:53 , May 29, 2019 |  BC Extra  |  Company News

Management tracks: Gilead replaces Hamill with BMS's Mercier; plus Alnylam, Audentes and more

Gilead Sciences Inc. (NASDAQ:GILD) hired Johanna Mercier as chief commercial officer, effective July 1, to assume the responsibilities of Laura Hamill, who is leaving nine months after joining the company as EVP of worldwide commercial...
17:44 , Apr 5, 2019 |  BC Week In Review  |  Clinical News

Black Diamond maps new class of glioblastoma mutations

Black Diamond showed in preclinical data presented at the American Association for Cancer Research (AACR) meeting why some EGFR mutations in glioblastoma multiforme (GBM) do not respond to early generation kinase inhibitors. The mutations occur...
18:28 , Jan 11, 2019 |  BC Week In Review  |  Financial News

NEA, RA Capital lead $85M B round for Black Diamond

Less than a month after its launch by Versant Ventures, Black Diamond Therapeutics Inc. (Cambridge, Mass.) has raised a tranched $85 million series B round to bring its two lead assets into the clinic and...
15:08 , Jan 10, 2019 |  BC Extra  |  Financial News

NEA, RA Capital lead $85M B round for Black Diamond

Less than a month after its launch by Versant Ventures, Black Diamond Therapeutics Inc. (Cambridge, Mass.) has raised a tranched $85 million series B round to bring its two lead assets into the clinic and...
20:30 , Dec 17, 2018 |  BioCentury  |  Finance

Versant’s base case

Versant Ventures plans to allocate more funding per start-up out of its newest funds, reflecting the firm’s shift towards building stand-alone companies with large portfolios. On Monday, Versant closed Versant Venture Capital VII at $600...
19:18 , Dec 14, 2018 |  BC Week In Review  |  Financial News

Versant launches Black Diamond to mine allosteric mutant oncogenes

Black Diamond Therapeutics Inc. (New York City, N.Y.) emerged from stealth on Dec. 11 with $20 million in a tranched series A round from Versant Ventures and a platform to find and drug allosteric mutant...
13:05 , Dec 11, 2018 |  BC Extra  |  Financial News

Versant launches Black Diamond to mine allosteric mutant oncogenes

Black Diamond Therapeutics Inc. (New York City, N.Y.) emerged from stealth on Tuesday with $20 million in a tranched series A round from Versant Ventures and a platform to find and drug allosteric mutant oncogenes...
13:03 , Dec 11, 2018 |  BC Innovations  |  Emerging Company Profile

Black Diamond: Mapping allostery

Black Diamond Therapeutics Inc. emerged from stealth on Tuesday with a platform to mine and drug baskets of allosteric mutant oncogenes using troves of human sequencing data that contain non-catalytic mutations previously deemed non-actionable. The...